Evidence map›Paper›PMID 34324704›Full record

ArticleEuropean journal of clinical investigation2021

SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1.

Sabrina Pagano, Sabine Yerly, Benjamin Meyer, Catherine Juillard, Noémie Suh, Christophe Le Terrier, Jean-Pierre Daguer, Lluc Farrera-Soler, Sofia Barluenga, Giovanni Piumatti and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sabrina PaganoDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-7075-1182
Sabine YerlyDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Benjamin MeyerCentre for Vaccinology, Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Catherine JuillardDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Noémie SuhDivision of Intensive Care, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.
Christophe Le TerrierDivision of Intensive Care, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.
Jean-Pierre DaguerFaculty of Science, Department of Organic Chemistry, NCCR Chemical Biology, University of Geneva, Geneva, Switzerland.
Lluc Farrera-SolerFaculty of Science, Department of Organic Chemistry, NCCR Chemical Biology, University of Geneva, Geneva, Switzerland.
Sofia BarluengaFaculty of Science, Department of Organic Chemistry, NCCR Chemical Biology, University of Geneva, Geneva, Switzerland.
Giovanni PiumattiDivision and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Oliver HartleyFaculty of Medicine, Department of Pathology and Immunology, University of Geneva, Switzerland.
Barbara LemaitreDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Christiane S EberhardtFaculty of Medicine, Departments of Pathology-Immunology and Pediatrics, University of Geneva, Geneva, Switzerland.
Claire-Anne SiegristDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Isabella EckerleGeneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
Silvia StringhiniDivision and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Idris GuessousDivision and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Laurent KaiserDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.
Jerome PuginDivision of Intensive Care, Geneva University Hospitals and the University of Geneva Faculty of Medicine, Geneva, Switzerland.
Nicolas WinssingerFaculty of Science, Department of Organic Chemistry, NCCR Chemical Biology, University of Geneva, Geneva, Switzerland.
Nicolas VuilleumierDivision of Laboratory Medicine, Department of Diagnostics and of Medical Specialties, Geneva University Hospitals and Geneva University, Geneva, Switzerland.

Funding

Center for Emerging Viral DiseasesFondation AncrageFondation de Bienfaisance du Groupe PictetFondation Ernst et Lucie SchmidheinyFondation Privée des HUGSwiss Federal Office of Public HealthThe De Reuter 657
6 · The paper itself

Abstract

backgroundUnravelling autoimmune targets triggered by SARS-CoV-2 infection may provide crucial insights into the physiopathology of the disease and foster the development of potential therapeutic candidate targets and prognostic tools. We aimed at determining (a) the association between anti-SARS-CoV-2 and anti-apoA-1 humoral response and (b) the degree of linear homology between SARS-CoV-2, apoA-1 and Toll-like receptor 2 (TLR2) epitopes.

designBioinformatics modelling coupled with mimic peptides engineering and competition experiments were used to assess epitopes sequence homologies. Anti-SARS-CoV-2 and anti-apoA-1 IgG as well as cytokines were assessed by immunoassays on a case-control (n = 101), an intensive care unit (ICU; n = 126) and a general population cohort (n = 663) with available samples in the pre and post-pandemic period.

resultsUsing bioinformatics modelling, linear sequence homologies between apoA-1, TLR2 and Spike epitopes were identified but without experimental evidence of cross-reactivity. Overall, anti-apoA-1 IgG levels were higher in COVID-19 patients or anti-SARS-CoV-2 seropositive individuals than in healthy donors or anti-SARS-CoV-2 seronegative individuals (P < .0001). Significant and similar associations were noted between anti-apoA-1, anti-SARS-CoV-2 IgG, cytokines and lipid profile. In ICU patients, anti-SARS-CoV-2 and anti-apoA-1 seroconversion rates displayed similar 7-day kinetics, reaching 82% for anti-apoA-1 seropositivity. In the general population, SARS-CoV-2-exposed individuals displayed higher anti-apoA-1 IgG seropositivity rates than nonexposed ones (34% vs 16.8%; P = .004).

conclusionCOVID-19 induces a marked humoral response against the major protein of high-density lipoproteins. As a correlate of poorer prognosis in other clinical settings, such autoimmunity signatures may relate to long-term COVID-19 prognosis assessment and warrant further scrutiny in the current COVID-19 pandemic.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralApolipoprotein A-IAutoantibodiesComputational BiologyCOVID-19CytokinesEpitopesFemaleHumansImmunity, HumoralImmunoglobulin GMaleMiddle AgedAntibodies, ViralApolipoprotein A-IAutoantibodiesCytokinesEpitopesImmunoglobulin GPeptide FragmentsPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TLR2 protein, humanToll-Like Receptor 2anti-apolipoprotein A-1 autoantibodiesCOVID-19molecular mimicryspike proteintoll-like receptor 2

Identifiers

PMID34324704
PMCPMC8420318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.